However, pCR rates differ between the diverse BC subgroups: 0–8% for luminal A, 15% for luminal B HER2-, 22–48% for luminal B HER2+ with trastuzumab combined in NAT, and more than 50% for HER2-enriched and triple-negative BC (TNBC) [12,13,14]. The gene discussed is ERBB2; the disease is breast cancer.